Fig 3. The effects of LLL12B, cisplatin, paclitaxel, and drug combination on cell viability.

MTT assays were performed to evaluate cell viability. A-D LLL12B inhibited cell viability of ovarian cancer cells, which were synergistically inhibited when LLL12B was combined with cisplatin or paclitaxel. The differences were found to be significantly different at *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.